Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 25.02M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -15.7M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 560 | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
| Dividend | N/A | Price/Book | 1.46 | EPS next 5Y | - | 52W High Chg | -59.00% |
| Recommedations | - | Quick Ratio | 0.32 | Shares Outstanding | 4.35M | 52W Low Chg | 108.00% |
| Insider Own | - | ROA | -46.42% | Shares Float | 249.56M | Beta | 2.08 |
| Inst Own | 7.06% | ROE | -186.37% | Shares Shorted/Prior | 18.77K/31.16K | Price | 1.04 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 192,279 | Target Price | - |
| Oper. Margin | -148,056,740.00% | Earnings Date | Jan 7 | Volume | 54,015 | Change | -4.59% |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited News